IL198082A0 - Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer - Google Patents

Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer

Info

Publication number
IL198082A0
IL198082A0 IL198082A IL19808209A IL198082A0 IL 198082 A0 IL198082 A0 IL 198082A0 IL 198082 A IL198082 A IL 198082A IL 19808209 A IL19808209 A IL 19808209A IL 198082 A0 IL198082 A0 IL 198082A0
Authority
IL
Israel
Prior art keywords
optionally substituted
ring
polo
treatment
alkyl
Prior art date
Application number
IL198082A
Other languages
English (en)
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0621205A external-priority patent/GB0621205D0/en
Priority claimed from GB0715614A external-priority patent/GB0715614D0/en
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Publication of IL198082A0 publication Critical patent/IL198082A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL198082A 2006-10-25 2009-04-07 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer IL198082A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0621205A GB0621205D0 (en) 2006-10-25 2006-10-25 Inhibitors of PLK
GB0715614A GB0715614D0 (en) 2007-08-10 2007-08-10 Inhibitors of plk
PCT/GB2007/003998 WO2008050096A1 (en) 2006-10-25 2007-10-19 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
IL198082A0 true IL198082A0 (en) 2009-12-24

Family

ID=38896021

Family Applications (1)

Application Number Title Priority Date Filing Date
IL198082A IL198082A0 (en) 2006-10-25 2009-04-07 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer

Country Status (13)

Country Link
US (1) US20100216802A1 (enExample)
EP (1) EP2079743B1 (enExample)
JP (1) JP2010507639A (enExample)
KR (1) KR20090071668A (enExample)
AT (1) ATE542820T1 (enExample)
AU (1) AU2007310604B2 (enExample)
BR (1) BRPI0718120A2 (enExample)
CA (1) CA2665736A1 (enExample)
EA (1) EA200900593A1 (enExample)
IL (1) IL198082A0 (enExample)
MX (1) MX2009004244A (enExample)
NZ (1) NZ577153A (enExample)
WO (1) WO2008050096A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
MX2009004279A (es) * 2006-10-30 2009-05-22 Chroma Therapeutics Ltd Hidroxamatos como inhibidores de histona desacetilasa.
CA2672612A1 (en) 2006-12-14 2008-06-26 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0807451D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
AU2009271663B2 (en) * 2008-06-23 2014-04-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
EP2356122B1 (en) 2008-06-23 2019-03-20 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
US20120220603A1 (en) * 2009-09-04 2012-08-30 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
SI2909175T1 (sl) 2012-10-17 2017-08-31 Macrophage Pharma Limited Terc-butil-n-(2-(4-(6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1 (2h)-il)-3,5-difluorofenil)etil)-l-alaninat ali njegova sol, hidrat ali solvat
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
US20160347750A1 (en) * 2014-01-31 2016-12-01 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
EP3833353A4 (en) * 2018-08-10 2022-08-24 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
CN111039944B (zh) 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 Mst1激酶抑制剂及其用途
KR102260995B1 (ko) * 2018-11-28 2021-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
CN115947728B (zh) * 2021-10-09 2024-01-09 沈阳药科大学 含磺酰基的二氢喋啶酮衍生物及其应用
WO2023158514A1 (en) 2022-02-18 2023-08-24 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization
CN118047779B (zh) * 2022-11-09 2025-02-11 沈阳药科大学 含苯联杂芳基的二氢喋啶酮衍生物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2006021547A1 (de) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinone als plk (polo like kinase) inhibitoren
JP2008510771A (ja) * 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用

Also Published As

Publication number Publication date
CA2665736A1 (en) 2008-05-02
WO2008050096A1 (en) 2008-05-02
MX2009004244A (es) 2009-05-14
KR20090071668A (ko) 2009-07-01
AU2007310604A1 (en) 2008-05-02
JP2010507639A (ja) 2010-03-11
NZ577153A (en) 2012-02-24
AU2007310604B2 (en) 2012-02-02
BRPI0718120A2 (pt) 2013-11-12
EP2079743A1 (en) 2009-07-22
EA200900593A1 (ru) 2010-06-30
US20100216802A1 (en) 2010-08-26
ATE542820T1 (de) 2012-02-15
EP2079743B1 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
IL198082A0 (en) Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
ES2524966T3 (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer
BR0316146A (pt) Derivados de amida do ácido 3-(2-hidróxifenil)-1h-pirazol-4-carboxìlico como inibidores de hsp90 para o tratamento de câncer
MX2012002059A (es) Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
PE20060842A1 (es) Amino-imidazolonas para la inhibicion de b-secretasa
MX2011007499A (es) Derivados de pirimidin-carboxamida como inhibidores de la cinasa syk.
SI1678166T1 (sl) Inhibitorji proteinske kinaze
PE20120506A1 (es) Derivados de pirazolopiridina como inhibidores de quinasas
TN2010000293A1 (en) Thiazole derivatives used as pi 3 kinase inhibitors
MX2008013583A (es) Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
TNSN07281A1 (en) Pyrazole derivatives for the inhibition of cdk's and gsk's
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
UA95976C2 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
MY169791A (en) Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
MX2009013218A (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus.
AR042042A1 (es) Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2011009146A (es) Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh.
PE20110213A1 (es) Derivados de indolinona como inhibidores de quinasa
MX2009008386A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer.
NZ592429A (en) PHENANTHROINDOLIZIDINE DERIVATIVE AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
WO2009072635A1 (ja) ヘテロ環化合物による造血幹細胞の増幅方法
WO2006123165A3 (en) Pyrimidine derivatives as hsp90 inhibitors